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A B S T R A C T
Background
An increase in serious adverse events with both regular formoterol and regular salmeterol in chronic asthma has been demonstrated in
previous Cochrane reviews.
Objectives
We set out to compare the risks of mortality and non-fatal serious adverse events in trials which have randomised patients with chronic
asthma to regular formoterol versus regular salmeterol.
Search methods
We identified trials using the Cochrane Airways Group Specialised Register of trials. We checked manufacturers’ websites of clinical
trial registers for unpublished trial data and also checked Food and Drug Administration (FDA) submissions in relation to formoterol
and salmeterol. The date of the most recent search was January 2012.
Selection criteria
We included controlled, parallel-design clinical trials on patients of any age and with any severity of asthma if they randomised patients
to treatment with regular formoterol versus regular salmeterol (without randomised inhaled corticosteroids), and were of at least 12
weeks’ duration.
Data collection and analysis
Two authors independently selected trials for inclusion in the review and extracted outcome data. We sought unpublished data on
mortality and serious adverse events from the sponsors and authors.
Main results
The review included four studies (involving 1116 adults and 156 children). All studies were open label and recruited patients who were
already taking inhaled corticosteroids for their asthma, and all studies contributed data on serious adverse events. All studies compared
formoterol 12 µg versus salmeterol 50 µg twice daily. The adult studies were all comparing Foradil Aerolizer with Serevent Diskus,
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and the children’s study compared Oxis Turbohaler to Serevent Accuhaler. There was only one death in an adult (which was unrelated
to asthma) and none in children, and there were no significant differences in non-fatal serious adverse events comparing formoterol to
salmeterol in adults (Peto odds ratio (OR) 0.77; 95% confidence interval (CI) 0.46 to 1.28), or children (Peto OR 0.95; 95% CI 0.06
to 15.33). Over a six-month period, in studies involving adults that contributed to this analysis, the percentages with serious adverse
events were 5.1% for formoterol and 6.4% for salmeterol; and over a three-month period the percentages of children with serious
adverse events were 1.3% for formoterol and 1.3% for salmeterol.
Authors’ conclusions
We identified four studies comparing regular formoterol to regular salmeterol (without randomised inhaled corticosteroids, but all
participants were on regular background inhaled corticosteroids). The events were infrequent and consequently too few patients have
been studied to allow any firm conclusions to be drawn about the relative safety of formoterol and salmeterol. Asthma-related serious
adverse events were rare and there were no reported asthma-related deaths.
P L A I N L A N G U A G E S U M M A R Y
Regular treatment with formoterol versus regular treatment with salmeterol in chronic asthma: serious adverse events
Asthma is a common condition that affects the airways - the small tubes that carry air in and out of the lungs. When a person with
asthma comes into contact with an irritant (an asthma trigger), the muscles around the walls of the airways tighten, the airways become
narrower, and the lining of the airways becomes inflamed and starts to swell. This leads to the symptoms of asthma - wheezing, coughing
and difficulty in breathing. They can lead to an asthma attack or exacerbation. People can have underlying inflammation in their lungs
and sticky mucus or phlegm may build up, which can further narrow the airways. There is no cure for asthma; however there are
medications that allow most people to control their asthma so they can get on with daily life.
Long-acting beta2-agonists, such as formoterol and salmeterol, work by reversing the narrowing of the airways that occurs during an
asthma attack. These drugs - taken by inhaler - are known to improve lung function, symptoms, quality of life and reduce the number
of asthma attacks. However, there are concerns about the safety of long-acting beta2-agonists, particularly in people who are not taking
inhaled corticosteroids to control the underlying inflammation.
We did this review to take a closer look at the safety of people taking formoterol daily compared to salmeterol daily. All participants
were prescribed regular background treatment with inhaled corticosteroids. We found three trials on 1116 adults and one trial on 156
children. There was not enough information to draw any conclusions on the relative safety of regular formoterol and regular salmeterol
in chronic asthma, but serious asthma-related events were rare, and only one non-asthma-related death was reported.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Regular formoterol compared to regular salmeterol for chronic asthma: SAEs
Patient or population: patients with asthma
Settings: community
Intervention: regular formoterol
Comparison: regular salmeterol
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Regular salmeterol Regular formoterol
All-cause mortality in
adults
Follow-up: mean 6
months
2 per 10001 0 per 1000
(-9 to 13)
See comment 1116
(3 studies)
⊕⊕©©
low2,3
No deaths were related to
asthma. Risks were cal-
culated from pooled risk
differences
All-cause mortality in
children
Follow-up: 3 months
See comment See comment See comment 156
(1 study)
⊕©©©
very low2,3,4
No deaths occurred in the
single small study on chil-
dren
All-cause SAEs in adults
Follow-up: mean 6
months
64 per 10001 50 per 1000
(30 to 80)
OR 0.77
(0.46 to 1.28)
1116
(3 studies)
⊕⊕©©
low2,3
All-cause SAEs in chil-
dren
Follow-up: 3 months
13 per 10001 12 per 1000
(1 to 168)
OR 0.95
(0.06 to 15.33)
156
(1 study)
⊕©©©
very low2,3,4
There was only one child
in each group with a seri-
ous adverse event
Asthma-related SAEs in
adults
Follow-up: mean 6
months
12 per 10001 10 per 1000
(4 to 30)
OR 0.86
(0.29 to 2.57)
1116
(3 studies)
⊕⊕©©
low2,3
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Asthma-related SAEs in
children
Follow-up: 3 months
See comment See comment Not estimable 156
(1 study)
⊕©©©
very low2,3,4
No asthma-related SAEs
in the single small study
on children
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio; OR: Odds ratio; SAE: serious adverse event
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Mean event rate in salmeterol arm of the included studies.
2 Unblinded studies.
3 Confidence intervals too wide to reach firm conclusions.
4 Only one small study found in children.
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B A C K G R O U N D
Whenpatients with asthma are not controlled by low-dose inhaled
corticosteroids alone, many asthma guidelines recommend addi-
tional long-acting beta2-agonists. Several Cochrane reviews have
addressed the efficacy of long-acting beta2-agonists in addition to
inhaled corticosteroids (Ni Chroinin 2005; Ni Chroinin 2009), in
comparison with placebo (Walters 2007), short-acting beta2-ago-
nists (Walters 2002), leukotriene-receptor antagonists (Ducharme
2006) and increased doses of inhaled corticosteroids (Greenstone
2005). The beneficial effects of long-acting beta2-agonists on lung
function, symptoms, quality of life and exacerbations requiring
oral steroids have been demonstrated. The pharmacology of beta2-
agonists is discussed in more detail in Appendix 1.
However, there is also longstanding controversy over the regular
use of beta2-agonists in asthma. Sears 1986 suggested that excessive
use of short-acting beta2-agonists might have contributed directly
or indirectly to increases in asthma deaths in New Zealand be-
tween 1960 and 1980. The authors commented that “most deaths
were associated with poor assessment, underestimation of sever-
ity and inappropriate treatment (over-reliance on bronchodilators
and under use of systemic corticosteroids), and delays in obtaining
help.”
Concern remains that the symptomatic benefit from treatment
with long-acting beta2-agonists might lead to underestimation of
attack severity in acute asthma, and could lead to an increase
in asthma-related deaths (as seen in SMART 2006). Further-
more, regular treatment with beta2-agonists can lead to toler-
ance to their bronchodilator effects and this phenomenon may
be more marked with longer-acting as opposed to shorter-act-
ing compounds (Lipworth 1997). A number of molecular mech-
anisms have been proposed to explain the possible detrimental ef-
fect of long-term beta2-agonist use in asthma, including desensi-
tisation due to receptor down regulation with cellular internalisa-
tion (Giembycz 2006).
A recent systematic review of the effect of long-acting beta2-ag-
onists on severe asthma exacerbations and asthma-related deaths
(Salpeter 2006) concluded that “long-acting beta-agonists have
been shown to increase severe and life-threatening asthma exac-
erbations, as well as asthma-related deaths”. Salpeter 2006 only
considered trials that compared long-acting beta2-agonists with
placebo, and the review was not able to include 28 trials in the
primary analysis (including nearly 6000 patients) because infor-
mation was not provided for asthma-related deaths.
Currently there are two long-acting beta2-agonists available, sal-
meterol and formoterol (also known as eformoterol). These two
drugs are known to have differences in speed of onset and re-
ceptor activity, and are used in different ways. Salmeterol has a
slower onset of action than formoterol and is not used as relief
medication, whereas formoterol can be used for maintenance and
relief of symptoms. Not all beta2-agonists carry the same risks,
as pointed out in the book entitled ’The Fenoterol Story’ (Pearce
2007). Appendix 2 discusses the possible mechanisms of increased
asthma mortality with beta-agonists in more detail.
Two published reviews have assessed the risk of serious adverse
events (SAEs) with regular salmeterol (Cates 2008) and formoterol
(Cates 2008a)without randomised inhaled corticosteroids in com-
parison to placebo or short-acting beta2-agonists, and further re-
views have compared regular formoterol and salmeterol when ran-
domised with an inhaled corticosteroid (Cates 2009; Cates 2009a;
Cates 2011; Jaeschke 2008; Jaeschke 2008a).
There is a need to systematically review all the available data
from controlled trials that have compared patients randomised
to regular formoterol or regular salmeterol without randomised
inhaled corticosteroids, although it is likely that such patients in
trials would already be prescribed background treatment with in-
haled corticosteroids. We considered all SAEs (fatal and non-fa-
tal), whether or not these were deemed by the investigators to be
related to trial medication.
O B J E C T I V E S
To assess the risk of mortality and non-fatal SAEs in trials which
have randomised patients with chronic asthma to regular for-
moterol versus regular salmeterol.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised trials (RCTs) of parallel design, with or
without blinding, in which patients with chronic asthma were
randomly assigned to regular treatment with formoterol versus
salmeterol. We excluded studies on acute asthma and exercise-
induced bronchospasm.
Types of participants
We included patients with a clinical diagnosis of asthma of any
age group, unrestricted by disease severity, previous or current
treatment.
Types of interventions
We included trials that randomised patients to receive inhaled for-
moterol versus salmeterol given regularly for a period of at least 12
weeks, but not randomised with inhaled corticosteroids. We ex-
cluded studies that used adjustable maintenance dosing and single
inhaler therapy (for maintenance and relief of symptoms).
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Types of outcome measures
Outcomes were not subdivided according to whether the trial in-
vestigators considered them to be related to trial medication.
Primary outcomes
1. All-cause mortality
2. All-cause non-fatal SAEs
Secondary outcomes
1. Asthma-related mortality
2. Asthma-related non-fatal SAEs
3. Cardiovascular-related mortality
An illustrative example of the definition of SAEs used in trials by
GlaxoSmithKline is shown in Appendix 3
Search methods for identification of studies
Electronic searches
We identified trials using theCochrane Airways Group Specialised
Register of trials, which is derived from systematic searches of
bibliographic databases including the Cochrane Central Regis-
ter of Controlled Trials (CENTRAL), MEDLINE, EMBASE,
CINAHL, AMED and PsycINFO, and handsearching of respi-
ratory journals and meeting abstracts (please see Appendix 4 for
further details). We searched all records in the Specialised Register
coded as ’asthma’ using the following terms:
(salmeterol or serevent) AND (formoterol or eformoterol or oxis
or foradil) AND (serious or safety or surveillance or mortality
or death or intubat* or adverse or toxicity or complications or
tolerability)
In addition we carried out a further search just using the terms:
(salmeterol or serevent) AND (formoterol or eformoterol or oxis
or foradil).
We conducted the latest searches in January 2012.
Searching other resources
We checked reference lists of all primary studies and review articles
for additional references. We also checked websites of clinical trial
registers for unpublished trial data and checked FDA submissions
in relation to formoterol.
Data collection and analysis
Selection of studies
Both review authors independently assessed studies identified in
the literature searches by examining titles, abstract and keywords
fields. We obtained studies that potentially fulfilled the inclusion
criteria in full text. We independently assessed these full-text trial
reports for inclusion. No disagreements occurred over the inclu-
sion or exclusion of studies.
Data extraction and management
CJC extracted data using a prepared checklist and entered them
into RevMan 5 (RevMan 2011). TL independently extracted the
results.Data included characteristics of included studies (methods,
participants, interventions, outcomes) and results of the included
studies. We contacted authors and sponsors of included studies
for unpublished adverse event data, and searched manufacturers’
websites for further details of adverse events. We also searched
FDA submissions. We recorded all-cause SAEs (fatal and non-
fatal) and, in view of the difficulty in deciding whether events are
asthma-related, we noted details of the cause of death and SAEs
where they were available. We also sought the definition of SAEs.
Assessment of risk of bias in included studies
CJC assessed the included studies for bias protection (including
sequence generation for randomisation, allocation concealment,
blinding of participants and assessors, loss to follow-up, complete-
ness of outcome assessment and other possible sources of bias),
and this was independently verified by TL.
Unit of analysis issues
We extracted data using the number of participants who suffered
one or more SAEs, in order to avoid double-counting events from
the same participant.
Assessment of heterogeneity
We assessed heterogeneity in the pooled odds ratio using the I2
statistic in RevMan 5 to indicate how much of the total hetero-
geneity found was between, rather than within, studies.
Data synthesis
The outcomes of this review were dichotomous and we recorded
the number of participants with each outcome event by allocated
treated group. We calculated pooled odds ratio (OR) and risk
difference (RD). The Peto OR has advantages when events are
rare, as no adjustment for zero cells is required. This property was
found in previous reviews to be more important than potential
problems with unbalanced treatment arms and large effect sizes,
and we therefore calculated the results for SAEs in RevMan 5 using
the Peto method with the Mantel-Haenszel method for sensitivity
analysis. We could not use funnel plots to assess publication bias,
as very few trials were identified.
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Subgroup analysis and investigation of heterogeneity
We planned to compare subgroups using tests for interaction
(Altman 2003). However, events were too sparse to allow a mean-
ingful comparison of the results in adults and children, and back-
ground non-randomised use of inhaled corticosteroids was used
in all studies, so subgroup analysis by background inhaled corti-
costeroid use was not possible.
Sensitivity analysis
We performed sensitivity analysis to assess the impact of the
method used to combine the study events (risk difference, Peto
OR and Mantel-Haenszel OR). The degree of bias protection in
the study designs was part of planned sensitivity analysis, but all
the studies were of open design and reporting of sequence gener-
ation and allocation concealment was poor.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies.
Results of the search
We carried out the original search in January 2009 and identified
40 references (155 references without the adverse event filter). We
identified three studies for inclusion (Condemi 2001; Everden
2004; Vervloet 1998) from the shorter list of references.When this
was rechecked against the unfiltered list we identified one further
study (Gabbay 1998), which had been published in abstract form
only in 1998, and found four further references related to the
three included studies.We identified 13 further studies for possible
inclusion, but we excluded them after more detailed inspection
(see Characteristics of excluded studies).
We carried out an updated search in January 2012 but there were
no new studies included.
Included studies
Of the four included studies, three enrolled a combined total of
1137 adults (Condemi 2001; Gabbay 1998; Vervloet 1998), and
one enrolled 156 children (Everden2004). Vervloet 1998 included
adults with reversible airways obstruction, and whilst they did not
seek to exclude participants with chronic obstructive pulmonary
disease (COPD), they indicated that most participants suffered
from asthma, so both review authors independently decided that
this study should be included.
All the studies compared a twice daily dose of formoterol 12 µg
with twice daily salmeterol 50 µg. Condemi 2001, Gabbay 1998
and Vervloet 1998 compared the Foradil Aerolizer with Serevent
Diskus inhaler devices, whilst Everden 2004 compared the Oxis
Turbohaler with Serevent Accuhaler. Although none of the studies
randomised patients to inhaled corticosteroids (in the form of
combined inhalers), all four studies randomised patients who were
already taking inhaled corticosteroids as background treatment.
All the studies were multi-centre, open (i.e. unblinded), parallel-
group design.
Condemi 2001, Gabbay 1998 and Vervloet 1998 were sponsored
byNovartis (manufacturer of Foradil) andEverden 2004was spon-
sored by AstraZeneca (manufacturer of Oxis).
Risk of bias in included studies
Allocation
Few details were available in relation to sequence generation or al-
location concealment. As all the studies were sponsored by Novar-
tis or AstraZeneca it is likely that they were adequately protected
from the risk of selection bias.
Blinding
All the studies were open-label in design, so unprotected against
performance bias. We remain uncertain as to the impact of this
on the outcomes primarily of interest to this review.
Incomplete outcome data
The adult studies had low dropout rates, but the study in children
had higher dropout rates and these were not balanced between the
trial arms. Thirty-three out of 127 children discontinued the study
(formoterol 21, salmeterol 12). All children who took at least one
dose of medication were included in the analysis.
Selective reporting
No serious adverse event data were published in the abstract of
Gabbay 1998, and no full publication has been identified after
correspondence with the author, who was unable to offer further
information. Vervloet 1998 also included information on all ad-
verse events only, but no separate data on SAEs. Novartis have
been able to provide data on file for SAEs in both of these studies.
An overview of the risks of bias is shown in Figure 1.
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Figure 1. Methodological quality summary: review authors’ judgements about each methodological quality
item for each included study.
Effects of interventions
See: Summary of findings for the main comparison Regular
formoterol compared to regular salmeterol for chronic asthma:
serious adverse events
All studies have contributed serious adverse event data to this re-
view: Condemi 2001 (528 adults studied for six months) and
Everden 2004 (156 children studies for three months) from pub-
lished papers and Gabbay 1998 (127 adults for three months) and
Vervloet 1998 (482 adults for six months) from data on file at
Novartis.
All-cause mortality
Nodeaths were reported in 528 adults in Condemi 2001. Novartis
have confirmed that there were no deaths in Gabbay 1998, and in
Vervloet 1998 there was one participant who died of heart disease
following coronary surgery in the salmeterol group. AstraZeneca
have confirmed that there were no deaths in the 156 children
in Everden 2004. There are insufficient data to draw any firm
conclusions in relation to mortality, but using the pooled risk
difference (RD) to combine the results of studies, the overall risk
difference in adults (RD -0.00; 95% confidence interval (CI) -
0.01 to 0.01) and in children (RD 0.00; 95% CI -0.02 to 0.02) is
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as shown in Figure 2. This indicates that the maximum absolute
difference between treatments in adults who have been studied is
one percentage point either way, and in children is two percentage
points either way. This range of uncertainty needs to be considered
in the context of a mortality rate of 0.05% found in studies on
formoterol alone (Cates 2008a).
Figure 2. Forest plot of comparison: 1 Regular formoterol versus regular salmeterol, outcome: 1.1 All-
cause mortality.
All-cause non-fatal serious adverse events (SAEs)
Adults
Condemi 2001 reported nine out of 262 adults having SAEs on
formoterol and 15 out of 266 on salmeterol, and in Vervloet 1998
there were non-fatal SAEs in 19 of 241 adults on formoterol and
21 out of 241 adults on salmeterol (Novartis data on file). Gabbay
1998 recorded only one patient with a serious adverse event (an
asthma exacerbation); the patient was not included in the safety
analysis for this trial as it could not be confirmed that any of the
study drug (salmeterol) had been taken. The Peto odds ratio (OR)
comparing formoterol to salmeterol was not significantly different
between groups (Peto OR 0.77; 95% CI 0.46 to 1.28 (Figure 3)),
norwas the risk difference (RD-0.01; 95%CI -0.04 to 0.01).Over
the six-month period for adults that contributed to this analysis
the percentages of adults with SAEs were formoterol 5.1% and
salmeterol 6.4%.
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Figure 3. Forest plot of comparison: 1 Regular formoterol versus regular salmeterol, outcome: 1.2 All-
cause SAEs.
We performed a sensitivity analysis to assess the addition of the
patient from Gabbay 1998 and this gave very similar results (Peto
OR 0.75; 95% CI 0.45 to 1.24). The OR was also virtually un-
changed using Mantel-Haenszel random (OR 0.77; 95% CI 0.46
to 1.29) or fixed method (OR 0.77; 95% CI 0.46 to 1.28).
Children
Everden 2004 reported one out of 80 children experiencing SAEs
on formoterol and one out of 76 children on salmeterol. Over
the three-month period the percentages of children with SAEs
were formoterol 1.3% and salmeterol 1.3%. The Peto OR was
not significantly different between groups (Peto OR 0.96; 95%
CI 0.06 to 15.52), nor was the risk difference (RD -0.0005; 95%
CI -0.04 to 0.04).
Asthma-related SAEs
Adults
Of all the SAEs reported in Condemi 2001, two adults on for-
moterol and three adults on salmeterol were classified as having
events related to asthma. In Vervloet 1998 there were four adults
in each group with events related to asthma. Again there is no sig-
nificant difference between the treatment groups (Peto OR 0.86;
95% CI 0.29 to 2.57 (Figure 4)).
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Figure 4. Forest plot of comparison: 1 Regular formoterol versus regular salmeterol, outcome: 1.3 Asthma-
related SAEs.
Sensitivity analysis to include the additional patient in Gabbay
1998 again gave very similar pooled results (Peto OR 0.76; 95%
CI 0.26 to 2.17).
Children
Neither of the SAEs in children in Everden 2004 were asthma-
related.
D I S C U S S I O N
Summary of main results
We identified only three studies involving adults (N = 1116) and
one study in children (N = 155) for inclusion in this review. Se-
rious adverse events (SAEs) were rare, especially those related to
asthma. Only one non-asthma-related death occurred. No signif-
icant differences in SAEs were found between regular formoterol
and regular salmeterol in adults or children with asthma. All of the
participants enrolled were taking inhaled corticosteroids at base-
line.
Overall completeness and applicability of
evidence
All of the studies enrolled patients whowere already taking inhaled
corticosteroids. Therefore it has not been possible to assess the
relative safety of formoterol and salmeterol in patients who were
not prescribed background inhaled corticosteroids, but this is no
longer considered acceptable practice.
Quality of the evidence
No double-blind trials have been carried out comparing regular
formoterol with regular salmeterol. The open studies included
in this review could have been influenced by the fact that the
participants and investigators were aware of the assigned treatment
for each patient, especially in studies sponsored by the companies
marketing one of the comparator medications.
Potential biases in the review process
Data on SAEs have been obtained for all of the included studies.
Agreements and disagreements with other
studies or reviews
Our two previous reviews (Cates 2008; Cates 2008a) indicated
an increase in all-cause SAEs when both regular formoterol and
regular salmeterol were compared with placebo. It would require
very large numbers of patients in head-to-head comparison trials to
determine whether there is any difference in SAEs between regular
formoterol and salmeterol, and it is perhaps not surprising that it
11Regular treatment with formoterol versus regular treatment with salmeterol for chronic asthma: serious adverse events (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
has not been possible to draw conclusions from this review, as the
number of participants in the included trials is relatively small.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Four unblinded studies have been identified comparing regular
formoterol to regular salmeterol. SAEs were infrequent and con-
sequently too few patients have been studied to allow firm conclu-
sions to be drawn. Asthma-related SAEs were rare and there were
no reported asthma-related deaths.
Implications for research
In order to compare the safety of regular formoterol and regular
salmeterol, much larger surveillance studies would need to be car-
ried out. Ideally these should be double-blind, double-dummy,
parallel-group studies.
A further review compares regular formoterol and salmeterol
when randomised together with additional inhaled corticosteroids
(Cates 2011).
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Condemi 2001
Methods Study design: a randomised, open-label, multicentre, parallel-group study over 6months
from September 1998 to June 1999 at 100 centres. Run-in: 1 week, long-acting beta2-
agonists appear to have been withdrawn.
Participants Population: 528 adults (18 to 75) years with moderate to moderately severe asthma
Baseline characteristics: mean age not stated. Concomitant inhaled corticosteroids used
by 100% of participants
Inclusion criteria: Outpatients between 18 and 75 years with moderate to moderately
severe asthma diagnosed at least 1 year before screening. Must have been receiving low-
dose inhaled corticosteroids at 400 µg/d (except fluticasone, 200 µg/d) for at least 1
month before screening, in addition to requiring a short-acting inhaled beta2-agonist at
least 4 times per week. Any long-acting beta2-agonists had to be discontinued at least
1 week before study entry. FEV1 % predicted between 40% to 80%, bronchodilator
reversibility by an increase of at least 12% in FEV1 after treatment with a beta2-agonist
bronchodilator at the screening visit or within 6 months before this visit
Exclusion criteria: pregnant or nursing women, and women of childbearing potential
who were not practising reliable contraception. Respiratory diseases unrelated to asthma
or other serious medical conditions, if they required a dose increase in inhaled corticos-
teroids to treat an acute exacerbation of asthma within 1 month before study entry. A
history of allergy to sympathomimetic amines, aerosols or inhaled lactose, Taking beta-
receptor-blocking medications, drugs that prolong the cardiac QT interval, tricyclic an-
tidepressants, monoamine oxidase derivatives or non-potassium-sparing diuretics
Interventions 1. Formoterol 12 µg BD (Foradil Aerolizer)
2. Salmeterol 50 µg BD (Serevent Diskus inhaler)
Delivery was DPI
Outcomes The primary end point was mean morning PEF measure 5 minutes after dosing. SAEs
reported (all-cause and asthma-related)
“No deaths were reported in either treatment arm. SAEs were reported in 7 patients
receiving formoterol (1 each, bronchospasm, chest pain, cholelithiasis, colon cancer,
dyspnea, fracture, syncope) and 12 patients receiving salmeterol (1 each, abdominal
pain, amnesia, appendicitis, bronchitis, cranial injury, fracture, glioma, intervertebral
disc disorder, metastases, myocardial infarction; 2, breast cancer). In addition, asthma
was reported as a serious adverse event in 2 patients receiving formoterol and 3 patients
receiving salmeterol.”
Notes Sponsored by Novartis
Risk of bias
Bias Authors’ judgement Support for judgement
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Condemi 2001 (Continued)
Random sequence generation (selection
bias)
Unclear risk No details of randomisation process
Allocation concealment (selection bias) Unclear risk No details of randomisation process
Blinding (performance bias and detection
bias)
All outcomes
High risk Open study
Incomplete outcome data (attrition bias)
All outcomes
Low risk 85.5% on formoterol and 88.7% on salme-
terol completed the study
Selective reporting (reporting bias) Low risk SAE results reported in the paper
Everden 2004
Methods Study design: an open randomised, double-blind, parallel-group study over 12 weeks
at 58 general practice centres (UK (56), Republic of Ireland(2)). Run-in 7 to 10 days
Participants Population: 156 children (6 to 17) years with moderate persistent asthma
Baseline characteristics: mean age 12 years. Concomitant inhaled corticosteroids used
by 100% of participants. PEF at randomisation 317.5 ± 110.4 (eformoterol) 311.5±
109.2 (salmeterol).
Inclusion criteria: outpatients aged 6 to 17 years, with a clinical diagnosis of moderate,
persistent asthma. Had to have been receiving ICS for asthma at a constant dose for
at least 4 weeks prior to enrolment, currently using inhaled short-acting beta2-agonists
for relief of asthma symptoms, and have had asthma symptoms occurring on at least 3
days or nights out of the past 7 days prior to enrolment. For randomisation, needed to
have continued to experience asthma symptoms and to have used at least 7 actuations
of short-acting b2-agonists in the last 7 days or nights for relief of asthma symptoms
Exclusion criteria: PEF predicted less than 50%, asthma symptoms requiring imme-
diate treatment, significant concurrent disease or health problems, or a requirement for
additional medication (e.g. ß-blocker therapy, nebulised therapy, oral steroids or oral
short-acting beta2-agonists) which may have interfered with the evaluation of the study
drug
Interventions 1. Formoterol 12 µg bid (Oxis Turbohaler, delivered dose 9 µg)
2. Salmeterol 50 µg bid (Accuhaler)
Delivery was DPI
Outcomes Primary outcome variable was the comparison of treatments via diary card assessment
of changes in daytime short-acting b2-agonist use during the 7 days prior to the final
(week 12) clinic visit. SAEs reported
“Two patients reported serious AEs, testicular torsion (eformoterol) and diabetesmellitus
(salmeterol), but neither were considered related to test treatment.”
Notes Sponsored by AstraZeneca
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Everden 2004 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation
scheme
Allocation concealment (selection bias) Unclear risk No details
Blinding (performance bias and detection
bias)
All outcomes
High risk Open
Incomplete outcome data (attrition bias)
All outcomes
Low risk 33 patients discontinued the study (for-
moterol 21, salmeterol 12). All patients
who took at least 1 dose of medication were
included in the analysis
Selective reporting (reporting bias) Low risk SAE data reported
Gabbay 1998
Methods Study design: 3-month, randomised, open, parallel-group, multicentre (55 centres)
general practice-based study. 2-week run-in period. From October 1995 to December
1996
Participants Population: 127 participants with asthma on regular maintenance anti-inflammatory
therapy, but still complained of night time symptoms
Baseline characteristics: mean age not stated. Concomitant inhaled corticosteroids used
by 100% of participants
Inclusion criteria: patients had to be at least 18 years or age with reversible obstructive
airways disease, with significant nocturnal symptoms at least twice per week and PEF
50% to 80% previous best at least 3 times per week during run-in. Concomitant inhaled
corticosteroids: all patients were on a stable dose of at least 400 µg BDP daily (or
equivalent)
Exclusion criteria: no details
Interventions 1. Formoterol 12 µg BD (Foradil Aerolizer)
2. Salmeterol 50 µg BD (Serevent Diskus inhaler)
Delivery was DPI
Outcomes Day and night symptoms, morning and evening pre-drug PEF, rescue medication use.
No information on adverse events found in abstract
Novartis have provided data on file indicating that there were no deaths in this study.
There was only 1 patient in the salmeterol group who suffered a SAE (asthma exacerba-
tion). This was not included in the safety analysis as there was no confirmation that the
patient had taken any study medication
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Gabbay 1998 (Continued)
Notes Sponsored by Novartis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No details
Allocation concealment (selection bias) Unclear risk No details
Blinding (performance bias and detection
bias)
All outcomes
High risk Open
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 106 of 127 randomised were analysed for
safety
Selective reporting (reporting bias) Low risk SAE data provided by Novartis
Vervloet 1998
Methods Study design: a randomised, open, multicentre, parallel-group study over 6 months
at 41 centres (France, Italy, Spain, Sweden, Switzerland, United Kingdom). Run-in 2
weeks
Participants Population: 482 adults (18 to 78) years with moderate to severe asthma
Baseline characteristics: mean age 48 years. Morning PEF 374, evening PEF 386.
Concomitant inhaled corticosteroids used by 100% of participants
Inclusion criteria: outpatients with a documented diagnosis of reversible obstructive
airways disease for 1 year or more, using regular inhaled corticosteroids at a constant
dose of at least 400 µg day (or 200 µg day fluticasone) for at least 1 month before
inclusion. No attempt was made to exclude reversible COPD but the authors state that
the vast majority of participants would have had asthma based on the inclusion criteria
Exclusion criteria: evidence of other clinically relevant diseases, pregnant or lactating
women, patients on beta-blocker therapy or with hypersensitivity to sympathomimetic
amines or inhaled lactose
Interventions 1. Formoterol 12 µg BD (Foradil Aerolizer)
2. Salmeterol 50 µg BD (Serevent Diskus inhaler)
Delivery was DPI
Outcomes Outcome: the primary efficacy variable was the mean morning pre-dose PEF during the
last 7 days of treatment
No reported data on SAEs or mortality in the paper but data on file obtained from
Novartis. 1 death occurred in the salmeterol group following myocardial infarction. 19
patients suffered a serious adverse event on formoterol and 22 on salmeterol (including
the 1 patient who died); 4 patients on formoterol and 4 on salmeterol suffered an
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Vervloet 1998 (Continued)
asthma-related serious adverse event, and 1 additional patient on formoterol developed
respiratory failure
Notes Sponsored by Novartis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-
generated randomisation scheme was used
to provide balanced blocks of patient num-
bers for the 2 treatment groups within each
country. A one-to-one treatment allocation
and a block size of 8 were used
Allocation concealment (selection bias) Unclear risk No details
Blinding (performance bias and detection
bias)
All outcomes
High risk Open
Incomplete outcome data (attrition bias)
All outcomes
Low risk 428/482 (89%) completed the study
Selective reporting (reporting bias) Low risk Full SAE data obtained from Novartis
AE: adverse event; BD: twice a day; COPD: chronic obstructive pulmonary disease; BDP: budesonide diphosphionate; DPI: dry
powder inhaler; FEV1: forced expiratory volume in one second; ICS: inhaled corticosteroids; PEF: peak expiratory flow; SAE: serious
adverse event
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Brambilla 2003 4-week study
Campbell 1999 8-week study, followed by 4-week cross-over to assess patient preference
Eryonucu 2005 Single-dose study
Heijerman 1999 6-week study
Larsson 1990 Review of 3 other studies
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(Continued)
Lemaigre 2006 Single-dose study
Novartis 2005 Comparison between different ways of using formoterol (no salmeterol arm)
Pohunek 2004 Single-dose cross-over study
Sill 1999 Single-dose study
van der Woude 2004 Single-dose study
van Veen 2003 Cross-over study of bronchodilator tolerance
Verini 1998 5-day treatment periods
Von Berg 2003 No salmeterol arm
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D A T A A N D A N A L Y S E S
Comparison 1. Regular formoterol versus regular salmeterol
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 All-cause mortality 4 1272 Risk Difference (M-H, Fixed, 95% CI) -0.00 [-0.01, 0.01]
1.1 Adults 3 1116 Risk Difference (M-H, Fixed, 95% CI) -0.00 [-0.01, 0.01]
1.2 Children 1 156 Risk Difference (M-H, Fixed, 95% CI) 0.0 [-0.02, 0.02]
2 All-cause SAEs 4 1272 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.77 [0.47, 1.28]
2.1 Adults 3 1116 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.77 [0.46, 1.28]
2.2 Children 1 156 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.95 [0.06, 15.33]
3 Asthma-related SAEs 4 1272 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.86 [0.29, 2.57]
3.1 Adults 3 1116 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.86 [0.29, 2.57]
3.2 Children 1 156 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 All-cause SAEs (Sensitivity
analysis)
4 1272 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.75 [0.46, 1.24]
4.1 Adults 3 1116 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.75 [0.45, 1.24]
4.2 Children 1 156 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.95 [0.06, 15.33]
5 Asthma-related SAEs (Sensitivity
analysis)
4 1272 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.76 [0.26, 2.17]
5.1 Adults 3 1116 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.76 [0.26, 2.17]
5.2 Children 1 156 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.0 [0.0, 0.0]
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Analysis 1.1. Comparison 1 Regular formoterol versus regular salmeterol, Outcome 1 All-cause mortality.
Review: Regular treatment with formoterol versus regular treatment with salmeterol for chronic asthma: serious adverse events
Comparison: 1 Regular formoterol versus regular salmeterol
Outcome: 1 All-cause mortality
Study or subgroup Formoterol Salmeterol
Risk
Difference Weight
Risk
Difference
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Adults
Condemi 2001 0/262 0/266 41.5 % 0.0 [ -0.01, 0.01 ]
Gabbay 1998 0/51 0/55 8.3 % 0.0 [ -0.04, 0.04 ]
Vervloet 1998 0/241 1/241 37.9 % 0.00 [ -0.02, 0.01 ]
Subtotal (95% CI) 554 562 87.7 % 0.00 [ -0.01, 0.01 ]
Total events: 0 (Formoterol), 1 (Salmeterol)
Heterogeneity: Chi2 = 0.40, df = 2 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 0.50 (P = 0.62)
2 Children
Everden 2004 0/80 0/76 12.3 % 0.0 [ -0.02, 0.02 ]
Subtotal (95% CI) 80 76 12.3 % 0.0 [ -0.02, 0.02 ]
Total events: 0 (Formoterol), 0 (Salmeterol)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Total (95% CI) 634 638 100.0 % 0.00 [ -0.01, 0.01 ]
Total events: 0 (Formoterol), 1 (Salmeterol)
Heterogeneity: Chi2 = 0.39, df = 3 (P = 0.94); I2 =0.0%
Test for overall effect: Z = 0.45 (P = 0.65)
Test for subgroup differences: Chi2 = 0.02, df = 1 (P = 0.89), I2 =0.0%
-0.1 -0.05 0 0.05 0.1
Favours formoterol Favours salmeterol
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Analysis 1.2. Comparison 1 Regular formoterol versus regular salmeterol, Outcome 2 All-cause SAEs.
Review: Regular treatment with formoterol versus regular treatment with salmeterol for chronic asthma: serious adverse events
Comparison: 1 Regular formoterol versus regular salmeterol
Outcome: 2 All-cause SAEs
Study or subgroup Formoterol Salmeterol
Peto
Odds Ratio
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Adults
Condemi 2001 9/262 15/266 0.60 [ 0.27, 1.37 ]
Gabbay 1998 0/51 0/55 0.0 [ 0.0, 0.0 ]
Vervloet 1998 19/241 21/241 0.90 [ 0.47, 1.71 ]
Subtotal (95% CI) 554 562 0.77 [ 0.46, 1.28 ]
Total events: 28 (Formoterol), 36 (Salmeterol)
Heterogeneity: Chi2 = 0.56, df = 1 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 1.01 (P = 0.31)
2 Children
Everden 2004 1/80 1/76 0.95 [ 0.06, 15.33 ]
Subtotal (95% CI) 80 76 0.95 [ 0.06, 15.33 ]
Total events: 1 (Formoterol), 1 (Salmeterol)
Heterogeneity: not applicable
Test for overall effect: Z = 0.04 (P = 0.97)
Total (95% CI) 634 638 0.77 [ 0.47, 1.28 ]
Total events: 29 (Formoterol), 37 (Salmeterol)
Heterogeneity: Chi2 = 0.58, df = 2 (P = 0.75); I2 =0.0%
Test for overall effect: Z = 1.00 (P = 0.32)
Test for subgroup differences: Chi2 = 0.02, df = 1 (P = 0.88), I2 =0.0%
0.01 0.1 1 10 100
Favours formoterol Favours salmeterol
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Analysis 1.3. Comparison 1 Regular formoterol versus regular salmeterol, Outcome 3 Asthma-related
SAEs.
Review: Regular treatment with formoterol versus regular treatment with salmeterol for chronic asthma: serious adverse events
Comparison: 1 Regular formoterol versus regular salmeterol
Outcome: 3 Asthma-related SAEs
Study or subgroup Formoterol Salmeterol
Peto
Odds Ratio
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Adults
Condemi 2001 2/262 3/266 0.68 [ 0.12, 3.94 ]
Gabbay 1998 0/51 0/55 0.0 [ 0.0, 0.0 ]
Vervloet 1998 4/241 4/241 1.00 [ 0.25, 4.04 ]
Subtotal (95% CI) 554 562 0.86 [ 0.29, 2.57 ]
Total events: 6 (Formoterol), 7 (Salmeterol)
Heterogeneity: Chi2 = 0.11, df = 1 (P = 0.74); I2 =0.0%
Test for overall effect: Z = 0.27 (P = 0.79)
2 Children
Everden 2004 0/80 0/76 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 80 76 0.0 [ 0.0, 0.0 ]
Total events: 0 (Formoterol), 0 (Salmeterol)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Total (95% CI) 634 638 0.86 [ 0.29, 2.57 ]
Total events: 6 (Formoterol), 7 (Salmeterol)
Heterogeneity: Chi2 = 0.11, df = 1 (P = 0.74); I2 =0.0%
Test for overall effect: Z = 0.27 (P = 0.79)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours formoterol Favours salmeterol
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Analysis 1.4. Comparison 1 Regular formoterol versus regular salmeterol, Outcome 4 All-cause SAEs
(Sensitivity analysis).
Review: Regular treatment with formoterol versus regular treatment with salmeterol for chronic asthma: serious adverse events
Comparison: 1 Regular formoterol versus regular salmeterol
Outcome: 4 All-cause SAEs (Sensitivity analysis)
Study or subgroup Formoterol Salmeterol
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Adults
Condemi 2001 9/262 15/266 36.6 % 0.60 [ 0.27, 1.37 ]
Gabbay 1998 0/51 1/55 1.6 % 0.15 [ 0.00, 7.36 ]
Vervloet 1998 19/241 21/241 58.6 % 0.90 [ 0.47, 1.71 ]
Subtotal (95% CI) 554 562 96.8 % 0.75 [ 0.45, 1.24 ]
Total events: 28 (Formoterol), 37 (Salmeterol)
Heterogeneity: Chi2 = 1.24, df = 2 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 1.13 (P = 0.26)
2 Children
Everden 2004 1/80 1/76 3.2 % 0.95 [ 0.06, 15.33 ]
Subtotal (95% CI) 80 76 3.2 % 0.95 [ 0.06, 15.33 ]
Total events: 1 (Formoterol), 1 (Salmeterol)
Heterogeneity: not applicable
Test for overall effect: Z = 0.04 (P = 0.97)
Total (95% CI) 634 638 100.0 % 0.75 [ 0.46, 1.24 ]
Total events: 29 (Formoterol), 38 (Salmeterol)
Heterogeneity: Chi2 = 1.27, df = 3 (P = 0.74); I2 =0.0%
Test for overall effect: Z = 1.12 (P = 0.26)
Test for subgroup differences: Chi2 = 0.03, df = 1 (P = 0.87), I2 =0.0%
0.01 0.1 1 10 100
Favours formoterol Favours salmeterol
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Analysis 1.5. Comparison 1 Regular formoterol versus regular salmeterol, Outcome 5 Asthma-related
SAEs (Sensitivity analysis).
Review: Regular treatment with formoterol versus regular treatment with salmeterol for chronic asthma: serious adverse events
Comparison: 1 Regular formoterol versus regular salmeterol
Outcome: 5 Asthma-related SAEs (Sensitivity analysis)
Study or subgroup Formoterol Salmeterol
Peto
Odds Ratio
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Adults
Condemi 2001 2/262 3/266 0.68 [ 0.12, 3.94 ]
Gabbay 1998 0/51 1/55 0.15 [ 0.00, 7.36 ]
Vervloet 1998 4/241 4/241 1.00 [ 0.25, 4.04 ]
Subtotal (95% CI) 554 562 0.76 [ 0.26, 2.17 ]
Total events: 6 (Formoterol), 8 (Salmeterol)
Heterogeneity: Chi2 = 0.85, df = 2 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 0.52 (P = 0.61)
2 Children
Everden 2004 0/80 0/76 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 80 76 0.0 [ 0.0, 0.0 ]
Total events: 0 (Formoterol), 0 (Salmeterol)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Total (95% CI) 634 638 0.76 [ 0.26, 2.17 ]
Total events: 6 (Formoterol), 8 (Salmeterol)
Heterogeneity: Chi2 = 0.85, df = 2 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 0.52 (P = 0.61)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours formoterol Favours salmeterol
A D D I T I O N A L T A B L E S
Table 1. Intrinsic efficacy of beta-agonists
Drug Intrinsic efficacy (%)
Isoprenaline, adrenaline 100
Fenoterol 42
Formoterol 20
Salbutamol 4.9
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Table 1. Intrinsic efficacy of beta-agonists (Continued)
Salmeterol < 2
Adapted fromHanania 2002. The authors acknowledge that it is difficult to determine the intrinsic efficacy of salmeterol given its high
lipophilicity.
A P P E N D I C E S
Appendix 1. Pharmacology of beta2-agonists
Beta2-agonists are thought to cause bronchodilation primarily through binding beta2-adrenoceptors on airways smooth muscle (ASM),
with subsequent activation of both membrane-bound potassium channels and a signalling cascade involving enzyme activation and
changes in intracellular calcium levels following a rise in cyclic adenosine monophosphate (cAMP) (Barnes 1993). However, beta2-
adrenoceptors are also expressed on a wide range of cell types where beta2-agonists may have a clinically significant effect including
airway epithelium (Morrison 1993), mast cells, post capillary venules, sensory and cholinergic nerves and dendritic cells (Anderson
2006). Beta2-agonists will also cross-react to some extent with other beta-adrenoceptors including beta1-adrenoceptors on the heart.
The in vivo effect of any beta2-agonist will depend on a number of factors relating to both the drug and the patient. The degree to
which a drug binds to one receptor over another is known as selectivity, which can be defined as absolute binding ratios to different
receptors in vitro, whilst functional selectivity is measured from downstream effects of drugs in different tissue types in vitro or in vivo.
All of the beta2-agonists described thus far are more beta2 selective than their predecessor isoprenaline in vitro. However, because
attempts to differentiate selectivity between the newer agents are confounded by so many factors, it is difficult to draw conclusions
about in vitro selectivity studies and probably best to concentrate on specific adverse side effects in human subjects at doses which
cause the same degree of bronchoconstriction. The potency of a drug refers to the concentration that achieves half the maximal receptor
activation of which that drug is capable but it is not very important clinically as for each drug, manufacturers will alter the dose to try
to achieve a therapeutic ratio of desired to undesired effects. In contrast efficacy refers to the ability of a drug to activate its receptor
independent of drug concentration. Drugs that fully activate a receptor are known as full agonists and those that partially activate a
receptor are known as partial agonists. Efficacy also is very much dependent on the system in which it is being tested and is affected
by factors including the number of receptors available and the presence of other agonists and antagonists. Thus whilst salmeterol acts
as a partial agonist in vitro it causes a similar degree of bronchodilation to the strong agonist formoterol in stable asthmatic patients
(van Noord 1996), presumably because there are an abundance of well-coupled beta2-adrenoceptors available with few downstream
antagonising signals. In contrast, with repetitive dosing formoterol is significantly better than salmeterol at preventing methacholine-
induced bronchoconstriction (Palmqvist 1999). These differences have led to attempts to define the “intrinsic efficacy” of a drug
independent of tissue conditions (Hanania 2002), as shown in Table 1. The clinical significance of intrinsic efficacy remains unclear.
Appendix 2. Possible mechanisms of increased asthma mortality with beta-agonists
Direct toxicity
This hypothesis states that direct adverse effects of beta2-agonists are responsible for an associated increase inmortality andmost research
in the area has concentrated on effects detrimental to the heart. Whilst it is often assumed that cardiac side effects of beta2-agonists
are due to cross-reactivity with beta1-adrenoceptors (i.e. poor selectivity), it is worth noting that human myocardium also contains
an abundance of beta2-adrenoceptors capable of triggering positive chronotropic and inotropic responses (Lipworth 1992). Indeed,
there is good evidence that cardiovascular side effects of isoprenaline (Arnold 1985) and other beta2-agonists including salbutamol
(Hall 1989) are mediated predominantly via cardiac beta2-adrenoceptors thus making the concept of in vitro selectivity less relevant.
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Generalised beta2-adrenoceptor activation can also cause hypokalaemia (Brown 1983) and it has been proposed that, through these
and other actions beta2-agonists may predispose to life-threatening dysrhythmias or cause other adverse cardiac effects.
During the 1960s epidemic most deaths occurred in patients with severe asthma and it was originally assumed that asthma and its
sequelae, including hypoxia, were the primary cause of death. However, mucus plugging and hypoxia does not preclude a cardiac event
as the final cause of death, and one might expect those with severe asthma to take more doses of a prescribed inhaler. As noted by Speizer
and Doll most deaths in the 1960s were in the 10 to 19 age group and “at these ages children have begun to act independently and
may be particularly prone to misuse a self-administered form of treatment” (Speizer 1968). If toxicity were related to increasing doses
of beta2-agonists one might expect most deaths to occur in hospital where high doses are typically used and this was not the case. One
possible explanation for this anomaly was provided by animal experiments in which large doses of isoprenaline caused little ill effect in
anaesthetised dogs with normal arterial oxygenation whereas much smaller doses caused fatal cardiac depression and asystole (although
no obvious dysrhythmia) when hypoxic (Collins 1969; McDevitt 1974). It has been hypothesised therefore that such events would be
less likely in hospital where supplemental oxygen is routinely given. The clinical relevance of these studies remains unclear although
there is some evidence of a synergistic effect between hypoxia and salbutamol use in asthmatic patients in reducing total peripheral
vascular resistance (Burggraaf 2001) - another beta2 mediated effect which could be detrimental to the heart during an acute asthma
attack through a reduction in diastolic blood pressure. Other potential mechanisms of isoprenaline toxicity include a potential increase
in mucous plugging and worsening of ventilation perfusion mismatch despite bronchodilation (Pearce 1990).
Further concerns about a possible toxic effect of beta2-agonists were raised during the New Zealand epidemic in the 1970s. In 1981
Wilson et al, who first reported the epidemic, reviewed 22 fatal cases of asthma and noted “In 16 patients death was seen to be sudden
and unexpected. Although all were experiencing respiratory distress, most were not cyanosed and the precipitate nature of their death
suggested a cardiac event, such as an arrest, inappropriate to the severity of their respiratory problem” (Wilson 1981). In humans,
fenoterol causes significantly greater chronotropic, inotropic and electrocardiographic side effects than salbutamol in asthmatic patients
(Wong 1990). Interestingly, across the same parameters fenoterol also causes more side effects than isoprenaline (Burgess 1991).
In patients with mild asthma and without a bronchoconstrictor challenge, salmeterol and salbutamol cause a similar degree of near
maximal bronchodilation at low doses (Bennett 1994). However, whilst as a one-off dose salbutamol is typically used at two to four
times the concentration of salmeterol, the dose equivalences for salmeterol versus salbutamol in increasing heart rate and decreasing
potassium concentration and diastolic blood pressure were 17.7, 7.8 and 7.6 respectively (i.e. salmeterol had a greater effect across
all parameters). Given the lower intrinsic efficacy of salmeterol (Table 1), these results highlight the importance of in vivo factors;
one possible explanation for the difference is the increased lipophilicity of salmeterol compared to salbutamol contributing to higher
systemic absorption (Bennett 1994).
When comparing increasing actuations of standard doses of formoterol and salmeterol inhalers in stable asthmatic patients, relatively
similar cardiovascular effects are seen at lower doses (Guhan 2000). However, at the highest doses (above those recommended by the
manufacturers) there were trends towards an increase in systolic blood pressure with formoterol; in comparison there was a trend towards
a decrease in diastolic blood pressure and an increase in QTc interval with salmeterol although no statistical analysis of the difference
was performed. In contrast in asthmatic patients with methacholine-induced bronchoconstriction there was no significant difference
between salmeterol and formoterol in causing increased heart rate and QTc interval although formoterol caused significantly greater
bronchodilation and hypokalaemia (Palmqvist 1999). Whilst there is good evidence of cardiovascular and metabolic side effects with
increasing doses of beta2-agonists, it is a little difficult to envisage serious adverse effects of this nature when using long-acting beta2-
agonists (LABAs) at manufacturer-recommended preventative doses. However, it is possible that some patients choose to use repeated
doses of LABAs during exacerbations.
Tolerance
In this setting, the term tolerance refers to an impaired response to beta2-agonists in patients who have been using regular beta2-
agonist treatment previously (Haney 2006). Tolerance is likely to result from a combination of reduced receptor numbers secondary to
receptor internalisation and reduced production and also uncoupling of receptors to downstream signalling pathways following repeated
activation (Barnes 1995). This phenomenon is likely to explain the beneficial reduction in systemic side effects seen with regular use of
beta2-agonists including salbutamol after one to two weeks (Lipworth 1989). However, the same effect on beta2-adrenoceptors in the
lung might be expected to produce a diminished response to the bronchodilating activity of beta2-agonists following regular use. In
patients with stable asthma, whilst there is some evidence of tolerance to both salbutamol (Nelson 1977) and terbutaline (Weber 1982)
other studies have been less conclusive (Harvey 1982; Lipworth 1989). However, evidence of tolerance to short and long-acting beta2-
agonists in both protecting against and reducing bronchoconstriction is much stronger in the setting of an acute bronchoconstrictor
challenge with chemical, allergen and ’natural’ stimuli (Haney 2006; Lipworth 1997).
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Studies comparing salmeterol and formoterol have shown that both cause tolerance compared to placebo but there was no significant
difference between the drugs (van der Woude 2001). There also appears to be little difference in the tolerance induced by regular
formoterol and regular salbutamol treatment (Hancox 1999; Jones 2001). To the authors’ knowledge no studies have looked specifically
at the degree of tolerance caused by isoprenaline and fenoterol in the setting of acute bronchoconstriction. Tolerance to bronchodilation
has been shown clearly to occur with addition of inhaled corticosteroids to salmeterol and formoterol (Lee 2003) and terbutaline (Yates
1996). There is conflicting evidence as to whether high-dose steroids can reverse tolerance in the acute setting (Jones 2001; Lipworth
2000).
At first glance the toxicity and tolerance hypothesesmight appear incompatible as systemic and cardiovascular tolerance ought to protect
against toxicity in the acute setting and there is good evidence that such tolerance occurs in stable asthmatic patients (Lipworth 1989).
However, whilst this study showed that changes in heart rate and potassium levels were blunted by previous beta2-agonist use, they
were not abolished; furthermore, at the doses studied these side effects appear to follow an exponential pattern (Lipworth 1989). In
contrast, in the presence of bronchoconstrictor stimuli the bronchodilator response to beta2-agonists follows a flatter curve (Hancox
1999; Wong 1990) and as previously discussed this curve is shifted downwards by previous beta2-agonist exposure (Hancox 1999).
Thus, it is theoretically possible that in the setting of an acute asthmatic attack and strong bronchoconstricting stimuli, bronchodilator
tolerance could lead to repetitive beta2-agonist use and ultimately more systemic side effects than would otherwise have occurred. Of
course, other sequelae of inadequate bronchodilation including airway obstruction will be detrimental in this setting.
Whilst the tolerance hypothesis is often cited as contributing towards the asthma mortality epidemics it is difficult to argue that
reduced efficacy of a drug can cause increased mortality relative to a time when that drug was not used at all. However, tolerance
to the bronchodilating effect of endogenous circulating adrenaline is theoretically possible and there is also evidence of rebound
bronchoconstriction when stopping fenoterol (Sears 1990), which may be detrimental. Furthermore, it appears that regular salbutamol
treatment can actually increase airway responsiveness to allergen (Cockcroft 1993) a potentially important effect that could form a
variant of the toxicity hypothesis. Differences between beta2-agonists in this regard are unclear, but the combination of rebound hyper
responsiveness and tolerance of the bronchodilator effect with regular beta2-agonist exposure has been recently advocated as a possible
mechanism to explain the association between beta2-agonists and asthma mortality (Hancox 2006a).
Other explanations
Confounding by severity
Historically, this hypothesis has been used extensively to try to explain the association between mortality and the use of fenoterol during
the 1970s New Zealand epidemic (see Pearce 2007) and is still quoted today. The hypothesis essentially relies on the supposition that
patients with more severe asthma are more likely to take either higher doses of beta2-agonists or a particular beta2-agonist (such as
fenoterol) thereby explaining the association. This hypothesis was carefully ruled out in the three case-control studies by comparing
the association between fenoterol and mortality in patients with varying severity of disease (Crane 1989; Grainger 1991; Pearce 1990).
Furthermore, the hypothesis cannot explain the overall increase in mortality in the 1960s and 1970s nor can it explain any significant
increase in mortality (whether taking inhaled steroids or not) from randomised controlled trial data.
The delay hypothesis
This hypothesis accepts that beta2-agonists or a particular beta2-agonist cause an increased risk of mortality but indirectly by causing
patients to delay before getting medical help and further treatments including high-dose steroids and oxygen. There is evidence that
both salmeterol and formoterol can reduce awareness of worsening underlying inflammation (Bijl-Hofland 2001; McIvor 1998). It
is difficult to rule out the delay hypothesis in either explaining or contributing towards both the asthma mortality epidemics and an
association with regular use of LABAs. There is evidence that beta2-agonists with higher intrinsic efficacy are more effective at relieving
bronchoconstriction in the acute setting (Hanania 2007) and could paradoxically cause patients to delay seekingmedical help for longer.
For the delay hypothesis to explain the increase in mortality during the 1960s and 1970s one has to imply that hospital treatment of
asthma when mortality rates were low during the earlier years of the 20th century was effective. It is difficult to say exactly how effective
such treatment is likely to have been.
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Reduced corticosteroid treatment
A slight but significant variation of the delay hypothesis suggests that patients who have separate beta2-agonists and corticosteroid
inhalers may choose to take less corticosteroid because of better symptom control from the inhaled beta2-agonists and it is reduced
corticosteroid treatment that contributes to a rise in mortality. It is rather difficult to see how this hypothesis explains the epidemics of
asthma deaths in the 1960s and 1970s relative to the 1920s and 30s (Figure 5), given that corticosteroids were not used for the treatment
of asthma in the earlier decades. If this hypothesis were to explain increased mortality from more recent randomised controlled trial
data one would not expect to see an increase in mortality in those taking LABAs alone.
Figure 5. Changes in asthma mortality (5 to 34 age group) in three countries in relation to the introduction
of isoprenaline forte in the UK and New Zealand and of fenoterol in New Zealand. (From Blauw 1995. With
permission from the Lancet).
Appendix 3. Definition of serious adverse event (SAE)
A SAE is any adverse event occurring at any dose that results in any of the following outcomes:
1. Death
2. A life-threatening adverse event
3. Inpatient hospitalisation or prolongation of existing hospitalisation
4. A disability/incapacity
5. A congenital anomaly in the offspring of a subject who received medication
6. Important medical events that may not result in death, be life-threatening or require hospitalisation may be considered a serious
adverse event when, based upon appropriate medical judgement, they may jeopardise the patient or subject and may require medical
or surgical intervention to prevent one of the outcomes listed in this definition. Examples of such medical events include allergic
bronchospasm requiring intensive treatment in an emergency room or at home, blood dyscrasias or convulsions that do not result in
inpatient hospitalisation, or the development of medication dependency or medication abuse.
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Clarifications
“Occurring at any dose” does not imply that the subject is receiving study medication.
Life-threatening means that the subject was, in the view of the investigator, at immediate risk of death from the event as it occurred.
This definition does not include an event that, had it occurred in a more severe form, might have caused death.
Hospitalisation for elective treatment of a pre-existing condition that did not worsen during the study is not considered an AE.
Complications that occur during hospitalisation are AEs. If a complication prolongs hospitalisation, the event is a SAE.
“Inpatient” hospitalisation means the subject has been formally admitted to a hospital for medical reasons. This may or may not be
overnight. It does not include presentation at a casualty or emergency room.
With regard to criterion number 6 above, medical and scientific judgement should be used in deciding whether prompt reporting is
appropriate in this situation.
Events or outcomes not qualifying as SAEs
The events or outcomes identified as asthma exacerbations will be recorded in the asthma exacerbations page of the case report form
(CRF) page if they occur. However, these individual events or outcomes, as well as any sign, symptom, diagnosis, illness and/or clinical
laboratory abnormality that can be linked to any of these events or outcomes, are not reported to GW as SAEs even though such event
or outcome may meet the definition of SAE, unless the following conditions apply:
• the investigator determines that the event or outcome qualifies as a SAE under criterion number 6 of the SAE definition (see
Section 7.2., Definition of a SAE), or the event or outcome is in the investigator’s opinion of greater intensity, frequency or duration
than expected for the individual subject, or death occurring for any reason during a study, including death due to a disease-related
event.
Appendix 4. Sources and search methods for the Cochrane Airways Group Specialised Register
(CAGR)
Electronic searches: core databases
Database Frequency of search
MEDLINE (Ovid) Weekly
EMBASE (Ovid) Weekly
CENTRAL (The Cochrane Library) Quarterly
PSYCINFO (Ovid) Monthly
CINAHL (EBSCO) Monthly
AMED (EBSCO) Monthly
Handsearches: core respiratory conference abstracts
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Conference Years searched
AmericanAcademyofAllergy, Asthma and Immunology (AAAAI) 2001 onwards
American Thoracic Society (ATS) 2001 onwards
Asia Pacific Society of Respirology (APSR) 2004 onwards
British Thoracic Society Winter Meeting (BTS) 2000 onwards
Chest Meeting 2003 onwards
European Respiratory Society (ERS) 1992, 1994, 2000 onwards
International PrimaryCareRespiratoryGroupCongress (IPCRG) 2002 onwards
Thoracic Society of Australia and New Zealand (TSANZ) 1999 onwards
MEDLINE search strategy used to identify trials for the CAGR
Asthma search
1. exp Asthma/
2. asthma$.mp.
3. (antiasthma$ or anti-asthma$).mp.
4. Respiratory Sounds/
5. wheez$.mp.
6. Bronchial Spasm/
7. bronchospas$.mp.
8. (bronch$ adj3 spasm$).mp.
9. bronchoconstrict$.mp.
10. exp Bronchoconstriction/
11. (bronch$ adj3 constrict$).mp.
12. Bronchial Hyperreactivity/
13. Respiratory Hypersensitivity/
14. ((bronchial$ or respiratory or airway$ or lung$) adj3 (hypersensitiv$ or hyperreactiv$ or allerg$ or insufficiency)).mp.
15. ((dust or mite$) adj3 (allerg$ or hypersensitiv$)).mp.
16. or/1-15
Filter to identify RCTs
1. exp “clinical trial [publication type]”/
2. (randomised or randomised).ab,ti.
3. placebo.ab,ti.
4. dt.fs.
5. randomly.ab,ti.
6. trial.ab,ti.
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7. groups.ab,ti.
8. or/1-7
9. Animals/
10. Humans/
11. 9 not (9 and 10)
12. 8 not 11
The MEDLINE strategy and RCT filter are adapted to identify trials in other electronic databases.
WH A T ’ S N E W
Last assessed as up-to-date: 5 January 2012.
Date Event Description
5 January 2012 New citation required but conclusions have not changed No new studies found.
5 January 2012 New search has been performed New search in January 2012but nonew studies included.
Minor edits made and plain language summary revised
H I S T O R Y
Protocol first published: Issue 2, 2009
Review first published: Issue 4, 2009
C O N T R I B U T I O N S O F A U T H O R S
CJC: conception of the idea and co-writing of protocol and review.
TL: co-writing of the protocol and review.
D E C L A R A T I O N S O F I N T E R E S T
None known.
S O U R C E S O F S U P P O R T
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Internal sources
• No sources of support supplied
External sources
• NHS R&D, UK.
National Institute of Health Research: Programme Grant
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
The ’Summary of findings’ table was not mentioned in the protocol and has been constructed on the basis of the primary outcomes
and asthma-related SAEs. Adults and children have been described separately in the ’Summary of findings’ table.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Adrenal Cortex Hormones [therapeutic use]; Adrenergic beta-Agonists [adverse effects]; Albuterol [adverse effects; ∗analogs & deriva-
tives]; Anti-Asthmatic Agents [∗adverse effects]; Asthma [∗drug therapy; mortality]; Chronic Disease; Ethanolamines [∗adverse effects];
Randomized Controlled Trials as Topic
MeSH check words
Adult; Child; Humans
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